GSK Expanding Fast - Oncology, HIV, And Smart Acquisitions
Source: SeekingAlpha
2026-03-18 08:00:22 ET
In the previous article, "GSK: Depemokimab and Jemperli Lead the Next Wave" , I talked primarily about Q3 earnings, the impact of the data from the Phase 2 study [ NCT04165772 ] on Jemperli's long-term prospects, and why, in my opinion, declining Zejula sales are no longer putting pressure on its stock....
Read the full article on Seeking Alpha
For further details see:
GSK Expanding Fast - Oncology, HIV, And Smart Acquisitions
Roche Holding Ltd ADR
NASDAQ: RHHBY
RHHBY Trading
-0.2% G/L:
$48.13 Last:
1,348,624 Volume:
$47.65 Open:
RHHBY Latest News
March 24, 2026 02:00:00 am
Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets
RHHBY Stock Data
$361,973,933,704
6,306,832,002
N/A
43
N/A
Pharmaceuticals
Healthcare
CH
Basel Switzerland
